Market revenue in 2020 | USD 13.3 million |
Market revenue in 2028 | USD 25.6 million |
Growth rate | 8.5% (CAGR from 2020 to 2028) |
Largest segment | Immunological disorders |
Fastest growing segment | Cardiovascular Disorders |
Historical data | 2016 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurological Disorders, Immunological Disorders, Hematology Diseases, Endocrine & Metabolism Diseases, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disease |
Key market players worldwide | Quest Diagnostics Inc, Centogene NV Ordinary Shares, Invitae Corp, Eurofins Scientific SE, PerkinElmer, Macrogenics Inc, Fulgent Genetics Inc, Myriad Genetics Inc, Labcorp Holdings Inc, OPKO Health Inc, 3billion, ARUP Laboratories, Strand Life Sciences, Ambry Genetics, REALM IDx, Inc., Baylor Genetics, Health Network Laboratories, PreventionGenetics, Biora Therapeutics, CooperSurgical, Artemis DNA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare disease genetic testing market will help companies and investors design strategic landscapes.
Immunological disorders was the largest segment with a revenue share of 13.53% in 2020. Horizon Databook has segmented the Netherlands rare disease genetic testing market based on neurological disorders, immunological disorders, hematology diseases, endocrine & metabolism diseases, cancer, musculoskeletal disorders, cardiovascular disorders, dermatology disease covering the revenue growth of each sub-segment from 2016 to 2028.
Introduction of national plan for rare diseases by the Dutch government in the country is anticipated to play crucial role in shaping the market growth in Netherlands. The Dutch Ministry of Health, Welfare, and Sport playing a pivotal role by allowing the Dutch Federation of University Medical Centers to develop and deploy a protocol for designating nationally recognized centers of expertise in the country in this area.
Furthermore, Orphanet Nederland and the Dutch Patient Alliance for Rare and Genetic Diseases have collaborated with the Dutch Federation of University Medical Centers to develop a designation procedure and thereby drive the disease managementi n the country. In addition, presence of a substantial number of rare disease registries including public & private in the country is expected to aid in revenue growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Netherlands rare disease genetic testing market , including forecasts for subscribers. This country databook contains high-level insights into Netherlands rare disease genetic testing market from 2016 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account